Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Equity Average: 2019-2023

Historic Equity Average for ADC Therapeutics (ADCT) over the last 3 years, with Sep 2023 value amounting to -$31.4 million.

  • ADC Therapeutics' Equity Average fell 128.52% to -$31.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$31.4 million, marking a year-over-year decrease of 128.52%. This contributed to the annual value of $39.8 million for FY2022, which is N/A change from last year.
  • As of Q3 2023, ADC Therapeutics' Equity Average stood at -$31.4 million, which was down 315.73% from $14.5 million recorded in Q2 2023.
  • ADC Therapeutics' 5-year Equity Average high stood at $270.9 million for Q2 2021, and its period low was -$31.4 million during Q3 2023.
  • Moreover, its 3-year median value for Equity Average was $93.7 million (2021), whereas its average is $112.0 million.
  • Per our database at Business Quant, ADC Therapeutics' Equity Average soared by 58,827.35% in 2020 and then tumbled by 128.52% in 2023.
  • Over the past 5 years, ADC Therapeutics' Equity Average (Quarterly) stood at $14,978 in 2019, then surged by 58,827.35% to $38.5 million in 2020, then soared by 460.28% to $93.7 million in 2021, then fell by 1.73% to $92.1 million in 2022, then crashed by 128.52% to -$31.4 million in 2023.
  • Its Equity Average was -$31.4 million in Q3 2023, compared to $14.5 million in Q2 2023 and $58.6 million in Q1 2023.